Patient-led Titration with Lantus(R) is Effective at Lowering Blood Glucose
Patient-led Titration with Lantus(R) is Effective at Lowering Blood Glucose
AsiaNet 53504
PARIS, France, June 24 / PRN=KYODO JBN/ --
- Self-empowerment for titration showed to be effective in ATLAS while
education helps managing the slightly increased hypoglycemia risk in
patient-led study arm -
Sanofi (EURONEXT : SAN and NYSE : SNY) announced today data from the Asian
Treat to Target Lantus(R) Study (ATLAS) showing that dosing of Lantus(R) (insulin
glargine) can be successfully self-adjusted by patients with type 2 diabetes to
achieve glycemic control or administered in a physician-led program.
Insulin therapy is widely established as an effective and well tolerated
treatment for the management of type 2 diabetes[1] and patient self-management
is key to optimizing treatment outcomes.[2] However, despite this, basal
insulin is not as widely adopted in Asia. Initiation from diagnosis is often
delayed[3] and target glucose lowering is rarely achieved due to insufficient
dose titration.
"Asian Treat to Target Lantus Study (ATLAS): A 24-Week Randomized,
Multinational Study" [Poster number: 940-P]
ATLAS, a randomized, multinational, 24-week study, compared the effectiveness
of a patient- versus physician-led initiation (usual standard of care) of
insulin glargine-based basal management. A total of 552 patients from Japan,
China, Pakistan, India, the Philippines, and Russia with type 2 diabetes were
randomly allocated to two titration arms: 275 patient-led, 277 physician-led.
Both treatment groups adjusted their insulin dose using the same algorithm to
achieve target fasting blood glucose levels of 110mg/dl.
Results show that patients with uncontrolled glucose levels can effectively
self-adjust their insulin glargine to lower their blood glucose to near target
levels, without increased occurrence of severe hypoglycemia versus
physician-led titration (0.7% vs. 0.7%), with higher nocturnal hypoglycemia
(16.4% vs. 6.5%, p=0.002), higher symptomatic hypoglycemia (36.0% vs. 25.6%,
p=0.02), and few unrelated serious adverse events (3.3% vs. 1.8%). Levels of
HbA1c decreased in both treatment arms by an average of 1.2% at week 12 and
1.3% at week 24. Notably, patients self-titrated up to a significantly higher
daily dose of insulin compared to the physician-led group, with a difference of
6.7 units/day (p<0.001) by week 24. In comparing the relative reduction of
average glucose concentration, patient-led titration was found to be superior
to physician-led titration, with a -0.15 change in mean HbA1c from baseline at
24 weeks (p=0.04).
"Evaluating the Patient Experience in the Asian Treat to Target Lantus Study
(ATLAS): A 24-Week, Randomized, Multinational Study" [Poster number: 1242-P]
Patients self-titrating basal insulin showed improvements in health-related
quality of life (QoL) scores comparable to levels scored by patients under
physician-led titration. Diabetes Treatment Satisfaction Questionnaire status
and change scores were similar between the two titration arms, with both groups
showing significant improvements at 24 weeks (p<0.001). Cross-country
differences in health-related QoL, as identified by the EuroQol EQ-5D patient
survey, were eliminated by the end of the study.
"Subjects with type 2 diabetes from Asia face specific challenges in managing
their condition and patient self-administration of insulin is sometimes
perceived as difficult, resulting in a very limited dose adjustment to reflect
the individual's insulin needs to achieve glycemic target," commented Satish
Garg, MD, Professor of Medicine and Pediatrics, University of Colorado, Denver,
and Editor-in-Chief of Diabetes Technology & Therapeutics. "ATLAS shows that a
broad range of patients, including Asians, can successfully lower blood glucose
by adjusting their insulin dose themselves. These findings could be translated
into future guidance in Asian countries that supports a self-management program
when patients start basal insulin therapy."
Results from ATLAS demonstrated that dose increase of Lantus(R) in patients with
type 2 diabetes new to insulin therapy in Asia, Russia and Japan, whether
self-titrated by patients themselves or supervised in a physician-led program,
is effective in achieving near target glycemic control on top of two oral
anti-diabetic medications. Results also showed that there was no difference in
the incidence of severe hypoglycemia. Also, patients initiating Lantus(R) by
self-titration may do so without compromising health-related QoL or treatment.
Pierre Chancel, Senior Vice President, Global Diabetes, Sanofi said: "As a
leader in integrated diabetes care, Sanofi focuses on providing simple and
convenient solutions to improve outcomes for people living with diabetes in
both developing and western countries. The results of ATLAS suggest that
Lantus(R) offers adaptable patient- or physician-led once-daily administration
suitable for a wide variety of patient populations."
About Diabetes
Diabetes is a chronic disease that occurs as type 1 diabetes, which is an
autoimmune disease characterized by the lack of insulin (the hormone that
regulates blood glucose concentrations) production by the pancreas, and type 2,
a metabolic disorder in which there are two main biological defects: a
deficient production of insulin and reduced ability of the body to respond to
the insulin being produced. Type 1 and type 2 diabetes are characterized by an
increase in blood glucose concentrations (hyperglycemia). Over time,
uncontrolled hyperglycemia leads to the macrovascular and microvascular
complications of diabetes. Macrovascular complications, which affect the large
blood vessels, include heart attack, stroke and peripheral vascular disease.
Microvascular complications affect the small blood vessels of the eyes
(retinopathy), kidney (nephropathy) and nerves (neuropathy). The global
incidence of diabetes is growing at an alarming rate, with more than 371
million people worldwide living with the condition today.[4]
About Sanofi Diabetes
Sanofi strives to help people manage the complex challenge of diabetes by
delivering innovative, integrated and personalized solutions. Driven by
valuable insights that come from listening to and engaging with people living
with diabetes, the Company is forming partnerships to offer diagnostics,
therapies, services and devices, including blood glucose monitoring systems.
Sanofi markets both injectable and oral medications for people with type 1 or
type 2 diabetes.
About Sanofi
Sanofi, an integrated global healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).
References
1. Inzucchi SE et al. Management of hyperglycaemia in type 2 diabetes: a
patient-centered approach. Position statement of the American Diabetes
Association (ADA) and the European Association for the Study of Diabetes
(EASD). Diabetologia 2012; 55: 1577-1596.
2. Davies M et al. Improvement of glycemic control in subjects with poorly
controlled type 2 diabetes. Diabetes Care 2005; 28: 1282-1288.
3. Khunti K et al. Self-titration of insulin in the management of people with
type 2 diabetes: a practical solution to improve management in primary care.
Diabetes, Obesity and Metabolism 2013; doi:10.1111/dom.12053. [Epub ahead of
print].
4. International Diabetes Federation. IDF Diabetes Atlas, 5th edition: 2012
update. Brussels, Belgium, 2011. http://www.idf.org/diabetesatlas (Accessed:
June, 2013)
Forward-Looking Statements
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include projections and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with respect to future
financial results, events, operations, services, product development and
potential, and statements regarding future performance. Forward-looking
statements are generally identified by the words "expects", "anticipates",
"believes", "intends", "estimates", "plans" and similar expressions. Although
Sanofi's management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally beyond the
control of Sanofi, that could cause actual results and developments to differ
materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and uncertainties
include among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA, regarding
whether and when to approve any drug, device or biological application that may
be filed for any such product candidates as well as their decisions regarding
labelling and other matters that could affect the availability or commercial
potential of such product candidates, the absence of guarantee that the product
candidates if approved will be commercially successful, the future approval and
commercial success of therapeutic alternatives, the Group's ability to benefit
from external growth opportunities, trends in exchange rates and prevailing
interest rates, the impact of cost containment policies and subsequent changes
thereto, the average number of shares outstanding as well as those discussed or
identified in the public filings with the SEC and the AMF made by Sanofi,
including those listed under "Risk Factors" and "Cautionary Statement Regarding
Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year
ended December 31, 2012. Other than as required by applicable law, Sanofi does
not undertake any obligation to update or revise any forward-looking
information or statements.
Source: Sanofi Diabetes
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。